Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26541961 | 0.82 | ALDH1A1 (0.44) | ALDH1A1LMNACYP1A2KDM4ECA12 | |
| SCHEMBL22600626 | 0.81 | LMNA (0.42) | ALDH1A1LMNACYP1A2KDM4ECA12 | |
| SCHEMBL4547019 | 0.79 | ALDH1A1 (0.61) | ALDH1A1LMNACYP1A2KDM4ECA12 | |
| SCHEMBL21207380 | 0.78 | LMNA (0.47) | ALDH1A1LMNACYP1A2KDM4ECA12 | |
| SCHEMBL7297373 | 0.75 | ALDH1A1 (0.50) | ALDH1A1LMNACYP1A2KDM4ECA12 | |
| SCHEMBL15693585 | 0.74 | CA12 (0.59) | ALDH1A1LMNACYP1A2KDM4ECA12 | |
| SCHEMBL7602303 | 0.74 | CA12 (0.59) | ALDH1A1LMNAKDM4ECA12CA7 | |
| SCHEMBL21210697 | 0.74 | LMNA (0.49) | ALDH1A1LMNACYP1A2KDM4ECA12 | |
| SCHEMBL21207459 | 0.74 | ALDH1A1 (0.41) | ALDH1A1LMNACYP1A2KDM4ECA12 | |
| SCHEMBL7856439 | 0.73 | ALDH1A1 (0.48) | ALDH1A1LMNACYP1A2KDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683280-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190233397-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683280-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885LMNA 4823/4885CYP1A2 4297/4885 |
| US-20190233397-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885LMNA 4823/4885CYP1A2 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.